Immunohistochemistry in the diagnosis of mucinous neoplasms involving the ovary: The added value of SATB2 and biomarker discovery through protein expression database mining

International Journal of Gynecological Pathology

Volumn 35, Issue 3, 2016, Pages 191-208

  Strickland, Sarah ^a,b   Wasserman, Jason K ^a,b   Giassi, Ana ^a   Djordjevic, Bojana ^a,b   Parra Herran, Carlos ^a,b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

IMMUNOHISTOCHEMISTRY; Ovarian mucinous neoplasms; POF1B; SATB2

Indexed keywords

BETA CATENIN; BIOLOGICAL MARKER; CYTOKERATIN 20; CYTOKERATIN 7; ESTROGEN RECEPTOR; MUCIN 1; MUCIN 2; MUCIN 5AC; PREMATURE OVARIAN FAILURE 1B; SATB2 PROTEIN; TRANSCRIPTION FACTOR CDX2; TRANSCRIPTION FACTOR PAX8; TUMOR MARKER; UNCLASSIFIED DRUG; MATRIX ATTACHMENT REGION BINDING PROTEIN; POF1B PROTEIN, HUMAN; PROTEIN; SATB2 PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ANAPLASTIC CARCINOMA; ARTICLE; BILIARY TRACT CANCER; CANCER DIAGNOSIS; CANCER RECURRENCE; CLINICAL FEATURE; COLORECTAL CARCINOMA; CONTROLLED STUDY; CYSTADENOMA; DATA BASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FOLLOW UP; GASTROINTESTINAL CARCINOMA; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARIAN MUCINOUS BORDERLINE TUMOR; OVARIAN MUCINOUS CYSTADENOMA; OVARIAN MUCINOUS NEOPLASM; OVARY ADENOCARCINOMA; OVARY CANCER; PANCREAS ADENOCARCINOMA; PANCREATOBILIARY ADENOCARCINOMA; PRIMARY OVARIAN MUCINOUS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; STOMACH ADENOCARCINOMA; TISSUE MICROARRAY; COLLOID CARCINOMA; GASTROINTESTINAL TUMOR; METABOLISM; OVARY; OVARY TUMOR; PATHOLOGY; PROTEIN DATABASE; PROTEOMICS; VALIDATION STUDY;

ADENOCARCINOMA, MUCINOUS; BIOMARKERS, TUMOR; DATABASES, PROTEIN; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; MATRIX ATTACHMENT REGION BINDING PROTEINS; OVARIAN NEOPLASMS; OVARY; PROTEINS; PROTEOMICS; TRANSCRIPTION FACTORS;

EID: 84946422806     PISSN: 02771691     EISSN: 15387151     Source Type: Journal    
DOI: 10.1097/PGP.0000000000000238     Document Type: Article

References (50)

1. Seidman JD, Horkayne-Szakaly I, Haiba M, et al. The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol Off J Int Soc Gynecol Pathol. 2004;23:41-4.
2. Rouzbahman M, Chetty R. Republished: Mucinous tumours of appendix and ovary: an overview and evaluation of current practice. Postgrad Med J. 2015;91:41-5.
3. Seidman JD, Kurman RJ, Ronnett BM. Primary and metastatic mucinous adenocarcinomas in the ovaries: incidence in routine practice with a new approach to improve intraoperative diagnosis. Am J Surg Pathol. 2003;27:985-93.
4. Yemelyanova AV, Vang R, Judson K, et al. Distinction of primary and metastatic mucinous tumors involving the ovary: analysis of size and laterality data by primary site with reevaluation of an algorithm for tumor classification. Am J Surg Pathol. 2008;32:128-38.
5. Khunamornpong S, Settakorn J, Sukpan K, et al. Primary ovarian mucinous adenocarcinoma of intestinal type: a clinicopathologic study of 46 cases. Int J Gynecol Pathol Off J Int Soc Gynecol Pathol. 2014;33:176-85.
6. Naik JD, Seligmann J, Perren TJ. Mucinous tumours of the ovary. J Clin Pathol. 2012;65:580-4.
7. Heatley MK. Mucinous tumours of the ovary - primary and metastatic. J Clin Pathol. 2012;65:577-9.
8. Leen SLS, Singh N. Pathology of primary and metastatic mucinous ovarian neoplasms. J Clin Pathol. 2012;65:591-5.
9. Lee KR, Young RH. The distinction between primary and metastatic mucinous carcinomas of the ovary: gross and histologic findings in 50 cases. Am J Surg Pathol. 2003;27: 281-92.
10. Khunamornpong S, Suprasert P, Pojchamarnwiputh S, et al. Primary and metastatic mucinous adenocarcinomas of the ovary: evaluation of the diagnostic approach using tumor size and laterality. Gynecol Oncol. 2006;101:152-7.
11. Lewis MR, Deavers MT, Silva EG, et al. Ovarian involvement by metastatic colorectal adenocarcinoma: still a diagnostic challenge. Am J Surg Pathol. 2006;30:177-84.
12. McCluggage WG. Immunohistochemistry in the distinction between primary and metastatic ovarian mucinous neoplasms. J Clin Pathol. 2012;65:596-600.
13. McCluggage WG, Wilkinson N. Metastatic neoplasms involving the ovary: a review with an emphasis on morphological and immunohistochemical features. Histopathology. 2005;47: 231-47.
14. Park SY, Kim HS, Hong EK, et al. Expression of cytokeratins 7 and 20 in primary carcinomas of the stomach and colorectum and their value in the differential diagnosis of metastatic carcinomas to the ovary. Hum Pathol. 2002;33:1078-85.
15. Ordóñez NG. Value of PAX 8 immunostaining in tumor diagnosis: a review and update. Adv Anat Pathol. 2012;19:140-51.
16. Wang M, Ma H, Pan Y, et al. PAX2 and PAX8 reliably distinguishes ovarian serous tumors from mucinous tumors. Appl Immunohistochem Mol Morphol AIMM Off Publ Soc Appl Immunohistochem. 2015;23(4):280-7.
17. Tabrizi AD, Kalloger SE, Köbel M, et al. Primary ovarian mucinous carcinoma of intestinal type: significance of pattern of invasion and immunohistochemical expression profile in a series of 31 cases. Int J Gynecol Pathol Off J Int Soc Gynecol Pathol. 2010;29:99-107.
18. Britanova O, Akopov S, Lukyanov S, et al. Novel transcription factor Satb2 interacts with matrix attachment region DNA elements in a tissue-specific manner and demonstrates cell-type-dependent expression in the developing mouse CNS. Eur J Neurosci. 2005;21:658-68.
19. Dragomir A, de Wit M, Johansson C, et al. The role of SATB2 as a diagnostic marker for tumors of colorectal origin: results of a pathology-based clinical prospective study. Am J Clin Pathol. 2014;141:630-8.
20. Magnusson K, de Wit M, Brennan DJ, et al. SATB2 in combination with cytokeratin 20 identifies over 95% of all colorectal carcinomas. Am J Surg Pathol. 2011;35:937-48.
21. Rizzolio F, Bione S, Villa A, et al. Spatial and temporal expression of POF1B, a gene expressed in epithelia. Gene Expr Patterns GEP. 2007;7:529-34.
22. Padovano V, Lucibello I, Alari V, et al. The POF1B candidate gene for premature ovarian failure regulates epithelial polarity. J Cell Sci. 2011;124:3356-68.
23. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecanrefractory metastatic colorectal cancer. N Engl J Med. 2004; 351:337-45.
24. Bang Y-J, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastrooesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687-97.
25. Hess V, A'Hern R, Nasiri N, et al. Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. J Clin Oncol Off J Am Soc Clin Oncol. 2004;22:1040-4.
26. Kikkawa F, Nawa A, Kajiyama H, et al. Clinical characteristics and prognosis of mucinous tumors of the ovary. Gynecol Oncol. 2006;103:171-5.
27. Shimada M, Kigawa J, Ohishi Y, et al. Clinicopathological characteristics of mucinous adenocarcinoma of the ovary. Gynecol Oncol. 2009;113:331-4.
28. Kelemen LE, Köbel M. Mucinous carcinomas of the ovary and colorectum: different organ, same dilemma. Lancet Oncol. 2011;12:1071-80.
29. Vang R, Gown AM, Barry TS, et al. Cytokeratins 7 and 20 in primary and secondary mucinous tumors of the ovary: analysis of coordinate immunohistochemical expression profiles and staining distribution in 179 cases. Am J Surg Pathol. 2006; 30:1130-9.
30. Ji H, Isacson C, Seidman JD, et al. Cytokeratins 7 and 20, Dpc4, and MUC5AC in the distinction of metastatic mucinous carcinomas in the ovary from primary ovarian mucinous tumors: Dpc4 assists in identifying metastatic pancreatic carcinomas. Int J Gynecol Pathol Off J Int Soc Gynecol Pathol. 2002;21:391-400.
31. Werling RW, Yaziji H, Bacchi CE, et al. CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: an immunohistochemical survey of 476 primary and metastatic carcinomas. Am J Surg Pathol. 2003;27:303-10.
32. Saad RS, Ghorab Z, Khalifa MA, et al. CDX2 as a marker for intestinal differentiation: its utility and limitations. World J Gastrointest Surg. 2011;3:159-66.
33. Dobreva G, Chahrour M, Dautzenberg M, et al. SATB2 is a multifunctional determinant of craniofacial patterning and osteoblast differentiation. Cell. 2006;125:971-86.
34. Döcker D, Schubach M, Menzel M, et al. Further delineation of the SATB2 phenotype. Eur J Hum Genet EJHG. 2014;22(8):1034-9.
35. Eberhard J, Gaber A, Wangefjord S, et al. A cohort study of the prognostic and treatment predictive value of SATB2 expression in colorectal cancer. Br J Cancer. 2012;106:931-8.
36. Wang S, Zhou J, Wang X-Y, et al. Down-regulated expression of SATB2 is associated with metastasis and poor prognosis in colorectal cancer. J Pathol. 2009;219:114-22.
37. Laury AR, Perets R, Piao H, et al. A comprehensive analysis of PAX8 expression in human epithelial tumors. Am J Surg Pathol. 2011;35:816-26.
38. Heidarpour M, Tavanafar Z. Diagnostic utility of PAX8 in differentiation of mullerian from non-mullerian tumors. Adv Biomed Res. 2014;3:96.
39. Tacha D, Zhou D, Cheng L. Expression of PAX8 in normal and neoplastic tissues: a comprehensive immunohistochemical study. Appl Immunohistochem Mol Morphol AIMM Off Publ Soc Appl Immunohistochem. 2011;19:293-9.
40. Chou Y-Y, Jeng Y-M, Kao H-L, et al. Differentiation of ovarian mucinous carcinoma and metastatic colorectal adenocarcinoma by immunostaining with beta-catenin. Histopathology. 2003;43:151-6.
41. Logani S, Oliva E, Arnell PM, et al. Use of novel immunohistochemical markers expressed in colonic adenocarcinoma to distinguish primary ovarian tumors from metastatic colorectal carcinoma. Mod Pathol Off J U S Can Acad Pathol Inc. 2005;18:19-25.
42. Kir G, Gurbuz A, Karateke A, et al. Clinicopathologic and immunohistochemical profile of ovarian metastases from colorectal carcinoma. World J Gastrointest Surg. 2010; 2:109-16.
43. Pinto-de-Sousa J, David L, Reis CA, et al. Mucins MUC1, MUC2, MUC5AC and MUC6 expression in the evaluation of differentiation and clinico-biological behaviour of gastric carcinoma. Virchows Arch Int J Pathol. 2002;440:304-10.
44. Wang J, El-Bahrawy MA. Expression profile of mucins in ovarian mucinous tumors: distinguishing primary ovarian from metastatic tumors. Int J Gynecol Pathol Off J Int Soc Gynecol Pathol. 2014;33:166-75.
45. Terada T. An immunohistochemical study of primary signetring cell carcinoma of the stomach and colorectum: II. Expression of MUC1, MUC2, MUC5AC, and MUC6 in normal mucosa and in 42 cases. Int J Clin Exp Pathol. 2013;6:613-21.
46. Feng H, Ghazizadeh M, Konishi H, et al. Expression of MUC1 and MUC2 mucin gene products in human ovarian carcinomas. Jpn J Clin Oncol. 2002;32:525-9.
47. Wang J, El-Bahrawy M. Expression profile of mucins (MUC1, MUC2, MUC5AC, and MUC6) in ovarian mucinous tumours: changes in expression from benign to malignant tumours. Histopathology. 2015;66:529-35.
48. Uhlén M, Fagerberg L, Hallström BM, et al. Proteomics. Tissue-based map of the human proteome. Science. 2015;23:347(6220).
49. Pontén F, Jirström K, Uhlen M. The Human Protein Atlas - a tool for pathology. J Pathol. 2008;216:387-93.
50. Parra-Herran CE, Yuan L, Nucci MR, et al. Targeted development of specific biomarkers of endometrial stromal cell differentiation using bioinformatics: the IFITM1 model. Mod Pathol Off J U S Can Acad Pathol Inc. 2014; 27:569-79.